MedTech Startup, Hedia, Aims to Improve Health Outcomes of Diabetics

December 24, 2021 | 2 minutes read

With an aim to control diabetes, Compehnhegan based MedTech startup, Hedia, raises €3 million for its technology.

Diabetes is becoming one of the most common diseases in the world. In the case of Type 1 diabetes, the patients have to rely on insulins to manage their sugar levels. To support the diabetics by improving the outcomes of diabetics, the MedTech startup, Hedia, raised €3 million in the latest funding round.

Moreover, the company is being backed by Novo-heirs. It was introduced in 2016 by a husband and wife, Peter Lucas and Christina Kildentoft. However, their business partner, Andreas Jespensgaard was also one of the founders.

The software of the company aims to help the patients who are using insulin with their management of the dose. It is very important to note that Lucas, himself is suffering from type 1 diabetes. Based on his own experiences, it was his idea to come up with Hedia to improve the health outcomes of the patients by improving their blood glucose levels.

Peter Lucas said: “My father also had type1 diabetes, and I got the diagnosis in my twenties. This is a very time-consuming disease if you don’t get the right help of managing it.”

The role of technology in the healthcare sector is remarkable. The applications of AI, Big Data, and cloud technologies are equipping the health industry with new powers.

Similarly, the startup claims that its platform is a diabetes assistant that wants to make life easier with diabetes. The Hedia App has an insulin calculator which calculates and recommends the insulin units of a person on the basis of data provided. Furthermore, these recommendations are based upon the user’s meal, physical activity, and current blood sugar level. The aim of this application is to allow the users to have stable blood glucose levels for a longer time.

However, the current funding will be very crucial for the startup to expand into different markets in Europe. Moreover, the company is also aiming to improve its support work on clinical studies. This is very important for Hedia to ensure its expansion on a global scale.